EVALUATION OF THE EFFECTIVENESS OF EMPAGLIFLOZIN IN THE TREATMENT OF CHRONIC HEART FAILURE IN OUTPATIENT AND CLINICAL PRACTICE

Abstract

Оbjective: To evaluate the clinical efficacy of empagli flozin in patients with chronic heart failure with reduced ejection fraction. Material and methods: The study was conducted at the multidisciplinary clinic of the Tashkent Medical Academy. The study included 40 patients with CHF II-IV functional class according to the classification of the New York Heart Association and reduced ejection fraction. 16 patients had coronary heart disease, 27 had arterial hypertension, 7 had combined pathology (CHD + hypertension), 8 had type 2 diabetes mellitus. The av erage age of patients was 59.2 ± 7.5 years. Results: The inclusion of empagliflozin in standard therapy for chronic heart failure with reduced ejection fraction demonstrated a decrease in NT-proBNP levels, an increase in left ventric ular ejection fraction, a decrease in heart failure symp toms and an improvement in the results of the six-minute walk test, which together contributed to an improvement in the quality of life of patients. Conclusions: Timely and competent therapy can not only restore the left ventric ular ejection fraction, but also improve the prognosis of patients.